Shares of Ariad have more than doubled in price over the past year, climbing sharply since the start of 2012, amid projections that ponatinib, its treatment for chronic myeloid leukemia, or CML, eventually could generate annual sales of more than $1 billion.
Ariad wins key patent for leukemia drug
Treatment could reach $1b in sales
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week